Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Jul 25, 2022 8:00 am EDT

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

Jul 05, 2022 8:00 am EDT

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations

Jul 04, 2022 2:30 pm EDT

Tracking News - More Details of Marketing Progress for IceSense3™ in Mainland China

Jun 15, 2022 8:00 am EDT

IceCure's ProSense® Featured at SIR 2022 Annual Meeting in Breast Cancer Cryoablation Categorical Course

Jun 13, 2022 8:00 am EDT

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China

Jun 09, 2022 8:00 am EDT

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil

May 18, 2022 7:00 am EDT

IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights

May 11, 2022 2:09 pm EDT

IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022

Apr 27, 2022 9:00 am EDT

IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology

Jan 31, 2022 8:00 am EST

IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023